Tauopathies are characterized by hyperphosphorylation of the microtubule-associated protein tau and its accumulation into fibrillar aggregates. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Oxidative stress is related to the pathogenesis of Alzheimer's disease (AD) characterized by progressive memory impairment. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
36/100
Alzheimer disease (AD) is characterized by cognitive impairment that starts with memory loss to end in dementia. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is the most common form of dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
There is a critical need to potentially individualize new strategies able to prevent and to slow down the progression of predementia and dementia syndromes. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Dopamine loss in the substantia nigra causes several of the motor signs seen in Parkinson's disease, but there is now increasing evidence highlighting the importance of cholinergic loss in the pathophysiology of nonmotor symptoms. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
These preliminary study results show an association between human brain activity of microglia, astrocytes, and IL-6 and delirium in elderly patients and add to the accumulating evidence that inflammatory mechanisms are involved in delirium. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
It is widely accepted that inflammation plays some role in the progression of chronic neurodegenerative diseases such as AD (Alzheimer's disease), but its precise role remains elusive. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Normal brain function is facilitated by a highly organized and interconnected structure allowing complex integration of sensory information and motor responses. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The contribution of specific psychotropic drugs to fall risk in patients with dementia has not been quantified precisely until now. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The current evidence base for ACP in dementia is limited. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Until relatively recently, most psychologists have had limited professional involvement with older adults. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The quality of end-of-life care exists on a continuum across care settings. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Design qualitative exploration of views from care home staff and the family of residents in care homes for older people. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The staff require education and support about discussing and implementing plans around care at the end of life in dementia and about cultural issues around death to improve practice. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Advance directives for euthanasia are never adhered to in the Netherlands in the case of people with advanced dementia, and their role in advance care planning and end-of-life care of people with advanced dementia is limited. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Instruments that assess quality when dying differ in several ways and most do not measure a single construct, which is relevant to guiding and evaluating care. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
One in three adults over the age of 60 years will die with dementia. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Delirium is a complex neuropsychiatric syndrome with generalized cognitive impairment and disproportionate inattention. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The hippocampus is known to support recollection memory, but the relation between its structure and recollection in healthy adults has not been established. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Chronic restraint stress (CRS) induces the remodeling (i.e., retraction and simplification) of the apical dendrites of hippocampal CA3 pyramidal neurons in rats, suggesting that intrahippocampal connectivity can be affected by a prolonged stressful challenge. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Major depression (MD) is one of the most prevalent psychiatric disorders and a leading cause of loss in work productivity. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Hippocampal atrophy is a biomarker of initial cognitive decline in PD, including impaired memory encoding and storage, suggesting heterogeneity in the neural substrate of memory impairment. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Hippocampal volume reductions and functional impairments are reliable findings in posttraumatic stress disorder (PTSD) imaging studies. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
A stressful event increases the risk of developing depression later in life, but the possible predisposing factors remain unknown. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →